Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension

This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril val-sartan in diabetic nephropathy (DN) patients with hypertension. One hundred and twelve DN patients with hypertension were enrolled. They were randomly divided into the control group (treated with nifedipine controlled-release tablets combined with valsartan) and the observation group (treated with nifedipine controlled-release tablets combined with sacubitril valsartan). Renal function, endothelial function and in-flammatory response were examined. After three-months treatment, the levels of clinical indexes (glycosylated hemoglobin, fasting blood glucose, systolic and diastolic blood pressure), renal function indicators (urinary al-bumin excretion rate, blood urea nitrogen, serum creatinine and cystatin C), endothelial function indicators (microalbumin, angiotensin II, thrombomodulin and cartilage oligomeric matrix protein) and inflammatory response factors (interleukin-6 and tumor necrosis factor-& alpha;) in the observation group were significantly lower than those in the control group. Nifedipine controlled-release tablets combined with sacubitril valsartan could effectively alleviate the progression of DN combined with hypertension.

Automated summary

This study evaluated the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in hypertensive diabetic nephropathy (DN) patients. The observation group, treated with the combination therapy, showed significantly lower levels of clinical indexes, renal function indicators, endothelial function indicators, and inflammatory response factors compared to the control group after three months of treatment.